Vistagen Phase 2 fasedienol study: safety met, numerical separation on primary; nominally significant in severe SAD

Vistagen Therapeutics, Inc.

Safety objective met: repeat dose fasedienol safety comparable to single dose, no new findings.
Primary endpoint (SUDS change) numerical separation from placebo but not statistically significant (pooled p=0.2).
In very severe SAD (LSAS≥95), pooled fasedienol showed nominally significant improvement (p=0.04, Cohen's d=0.78).
CGI-I and PGI-C responder rates directionally higher for fasedienol; repeat dose arm >2x placebo.
Exploratory anticipatory anxiety endpoint: repeat dose (p=0.01) and pooled (p=0.03) nominal significance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.